Cargando…
Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions
Real-world data (RWD) and real-world evidence (RWE) have garnered great interest for supporting drug research and development (R&D) by medical researchers and regulators in recent years. The application and development of RWD/E in drug regulatory decision-making have been vigorously promoted in...
Autores principales: | Li, Pei, Wang, Su, Chen, Yuwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579147/ https://www.ncbi.nlm.nih.gov/pubmed/37624556 http://dx.doi.org/10.1007/s43441-023-00555-9 |
Ejemplares similares
-
Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan
por: Hiramatsu, Katsutoshi, et al.
Publicado: (2021) -
Shared decision-making in the People’s Republic of China: current status and future directions
por: Huang, Rongchong, et al.
Publicado: (2015) -
Real-world evidence for regulatory decision-making: updated guidance from around the world
por: Burns, Leah, et al.
Publicado: (2023) -
Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022) -
Use of real world data to improve drug coverage decisions in China
por: Wang, Wen, et al.
Publicado: (2023)